Abstract
Tumor relapse after radiotherapy may be due to the upregulation of programmed cell death ligand 1 (PD-L1). We demonstrated that anti-PD-L1 antibody synergizes with radiation to control local and distal tumors. CD8+T cells mediated antitumor effects of the combination therapy by the reduction of myeloid-derived suppressor cells (MDSCs) via tumor-necrosis factor (TNF)-mediated signaling. Our study provides insight into immune- and radiation-based combinational therapies.
Original language | English (US) |
---|---|
Article number | e28499 |
Journal | OncoImmunology |
Volume | 3 |
Issue number | 4 |
DOIs | |
State | Published - 2014 |
Keywords
- Antibody therapy
- Myeloid-derived suppressor cell
- Negative signal
- PD-L1
- Radiation therapy
- T-cell activation
- TNF
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology